Please login to the form below

Not currently logged in
Email:
Password:

biosimilar

This page shows the latest biosimilar news and features for those working in and with pharma, biotech and healthcare.

AbbVie preps uterine fibroid filing after phase 3 win

reducing its reliance on $16bn immunology blockbuster Humira (adalimumab), due to face biosimilar competition in Europe later this year and in the US in 2023.

Latest news

  • Roche and AbbVie prepare to move Venclexta into first-line CLL Roche and AbbVie prepare to move Venclexta into first-line CLL

    Venclexta is a key growth product for both companies and, with Rituxan facing the threat of biosimilar competition, Roche also needs to generate more momentum for Gazyva.

  • Amgen CEO says Aimovig is “one of most successful launches” Amgen CEO says Aimovig is “one of most successful launches”

    As biosimilars start to eat into sales of its blockbuster biologic drugs, Amgen needs new products to deliver growth – and it says migraine therapy Aimovig is off to a great start. ... of weakness from biosimilar competition after Mylan/Biocon launched

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars. ... This week saw the company unveil strong Q3 results, which managed to

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimer’s data

    Along with a useful contribution from biosimilars, that cushioned the impact of flat sales for Biogen’s multiple sclerosis franchise, headed by Tecfidera (dimethyl fumarate), which has been hit by competition

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    Some analysts had predicted Roche would see sales decline around 9% this year due to biosimilar competition. ... As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in

More from news
Approximately 130 fully matching, plus 309 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 51 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 18 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics